Circulation, Vol 79, 188-197, Copyright © 1989 by American Heart Association
T Munzel, J Holtz, A Mulsch, DJ Stewart and E Bassenge
N-acetylcysteine is assumed to reverse nitrate tolerance by replenishing
depleted intracellular sulfhydryl groups, but data on interactions of
N-acetylcysteine and nitrates in patients with stable angina are
controversial and disappointing. Therefore, we studied the effect of
N-acetylcysteine on nitrate responsiveness of epicardial arteries and of
the venous system (assessed as changes in effective vascular compliance) in
dogs (n = 12) during long-term nitroglycerin treatment (1.5
micrograms/kg/min i.v. for 5-6 days). In dogs with nitroglycerin-specific
tolerance (shift of venous or epicardial artery dilation to 15-17-fold
higher dosages), N-acetylcysteine (100 mg/kg i.v.) had no dilator effect
and did not alter the dose-response relations of nitroglycerin. Yet, in
nontolerant dogs (n = 17), N- acetylcysteine augmented (1.5-2.0-fold) the
dilation of epicardial arteries and the reduction of peripheral vascular
resistance induced by 0.5-1.5 micrograms/kg/min nitroglycerin. In vitro,
the augmentation of purified guanylate cyclase activity by nitroglycerin
(10-100 microM) was potentiated by N-acetylcysteine (0.01-1.0 mM) in saline
or in canine plasma, but N-acetylcysteine alone was ineffective. We
conclude that 1) N-acetylcysteine does not restore nitroglycerin
responsiveness in tolerant epicardial arteries or veins in vivo, 2) a
small, tolerance- independent augmentation of nitroglycerin-induced
dilation may result from N-acetylcysteine-induced extracellular formation
of a stimulant of guanylate cyclase from nitroglycerin.
ARTICLES
Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist
Institute of Applied Physiology, University of Freiburg, FRG.
This article has been cited by other articles:
![]() |
R. Parent, N. Leblanc, and M. Lavallee Nitroglycerin reduces myocardial oxygen consumption during exercise despite vascular tolerance Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1226 - H1234. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamamoto and R. J. Bing Nitric Oxide Donors Experimental Biology and Medicine, December 1, 2000; 225(3): 200 - 206. [Abstract] [Full Text] |
||||
![]() |
P. R. A. Caramori, A. G. Adelman, E. R. Azevedo, G. E. Newton, A. B. Parker, and J. D. Parker Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1969 - 1974. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zhang, A. Ohara, T. Mashimo, J. Sun, S. Shibuta, K. Takada, H. Kosaka, M. Terada, and I. Yoshiya Cardiovascular Effects of an Ultra–Short-Acting Nitric Oxide–Releasing Compound, Zwitterionic Diamine/NO Adduct, in Dogs Circulation, November 1, 1996; 94(9): 2235 - 2240. [Abstract] [Full Text] |
||||
![]() |
T. Munzel and E. Bassenge Long-term Angiotensin-Converting Enzyme Inhibition With High-Dose Enalapril Retards Nitrate Tolerance in Large Epicardial Arteries and Prevents Rebound Coronary Vasoconstriction In Vivo Circulation, June 1, 1996; 93(11): 2052 - 2058. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |